SEARCH

SEARCH BY CITATION

References

  • 1
    World Cancer Research Fund/American Institute for Cancer Research, Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective. International Report. Washington, D.C.: AICR, 2007.
  • 2
    Wang GJ,Volkow ND,Logan J,Pappas NR,Wong CT,Zhu W,Netusil N,Fowler JS. Brain dopamine and obesity. Lancet 2001; 357: 3547.
  • 3
    Eisenhofer G,Aneman A,Friberg P,Hooper D,Fandriks L,Lonroth H,Hunyady B,Mezey E. Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab 1997; 82: 386471.
  • 4
    Hernandez DE,Mason GA,Walker CH,Valenzuela JE. Dopamine receptors in human gastrointestinal mucosa. Life Sci 1987; 41: 271723.
  • 5
    Rubi B,Ljubicic S,Pournourmohammadi S,Carobbio S,Armanet M,Bartley C,Maechler P. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J Biol Chem 2005; 280: 3682432.
  • 6
    Duan J,Wainwright MS,Comeron JM,Saitou N,Sanders AR,Gelernter J,Gejman PV. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 2003; 12: 20516.
  • 7
    Li T,Arranz M,Aitchison KJ,Bryant C,Liu X,Kerwin RW,Murray R,Sham P,Collier DA. Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia. Schizophr Res 1998; 32: 8792.
  • 8
    Ritchie T,Noble EP. Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res 2003; 28: 7382.
  • 9
    Gemignani F,Landi S,Moreno V,Gioia-Patricola L,Chabrier A,Guino E,Navarro M,Cambray M,Capella G,Canzian F. Polymorphisms of the dopamine receptor gene DRD2 and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 16338.
  • 10
    Lanza E,Schatzkin A,Ballard-Barbash R,Corle D,Clifford C,Paskett E,Hayes D,Bote E,Caan B,Shike M,Weissfeld J,Slattery M, et al. The polyp prevention trial II: dietary intervention program and participant baseline dietary characteristics. Cancer Epidemiol Biomarkers Prev 1996; 5: 38592.
  • 11
    Schatzkin A,Lanza E,Freedman LS,Tangrea J,Cooper MR,Marshall JR,Murphy PA,Selby JV,Shike M,Schade RR,Burt RW,Kikendall JW, et al. The polyp prevention trial I: rationale, design, recruitment, and baseline participant characteristics. Cancer Epidemiol Biomarkers Prev 1996; 5: 37583.
  • 12
    Block G,Hartman AM,Dresser CM,Carroll MD,Gannon J,Gardner L. A data-based approach to diet questionnaire design and testing. Am J Epidemiol 1986; 124: 45369.
  • 13
    Mares-Perlman JA,Klein BE,Klein R,Ritter LL,Fisher MR,Freudenheim JL. A diet history questionnaire ranks nutrient intakes in middle-aged and older men and women similarly to multiple food records. J Nutr 1993; 123: 489501.
  • 14
    The Practical Guide: Identification, Evaluation and Treatment of Overweight and Obesity in Adults. National Institutes of Health, National Heart, Lung, and Blood Institute, and North American Association for the Study of Obesity. Bethesda, MD: National Institute of Health Publication (00-4084), 2000.
  • 15
    Sansbury LB,Bergen AW,Wanke KL,Yu B,Caporaso NE,Chatterjee N,Ratnasinghe L,Schatzkin A,Lehman TA,Kalidindi A,Modali R,Lanza E. Inflammatory cytokine gene polymorphisms, nonsteroidal anti-inflammatory drug use, and risk of adenoma polyp recurrence in the polyp prevention trial. Cancer. Epidemiol. Biomarkers. Prev. 2006; 15: 494501.
  • 16
    Kokoris M,Dix K,Moynihan K,Mathis J,Erwin B,Grass P,Hines B,Duesterhoeft A. High-throughput SNP genotyping with the Masscode system. Mol Diagn 2000; 5: 32940.
  • 17
    Arinami T,Gao M,Hamaguchi H,Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997; 6: 57782.
  • 18
    Pohjalainen T,Rinne JO,Nagren K,Lehikoinen P,Anttila K,Syvalahti EK,Hietala J. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998; 3: 25660.
  • 19
    Basu S,Dasgupta PS. Decreased dopamine receptor expression and its second-messenger cAMP in malignant human colon tissue. Dig Dis Sci 1999; 44: 91621.
  • 20
    Blum K,Sheridan PJ,Wood RC,Braverman ER,Chen TJ,Cull JG,Comings DE. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med 1996; 89: 396400.
  • 21
    Lin S-C,Wu P-L,Ko H-C,Wu JY-W,Huang S-Y,Lin W-W,Lu R-B. Specific personality traits and dopamine, serotonin genes in anxiety-depressive alcoholism among Han Chinese in Taiwan. Prog Neuro-Psychopharmacol Biol Psychiatry 2007; 31: 152634.
  • 22
    Morton LM,Wang SS,Bergen AW,Chatterjee N,Kvale P,Welch R,Yeager M,Hayes RB,Chanock SJ,Caporaso NE. DRD2 genetic variation in relation to smoking and obesity in the Prostate. Lung Colorectal, and Ovarian Cancer Screening Trial. Pharmacogenet Genomics 2006; 16: 90110.
  • 23
    Nisoli E,Brunani A,Borgomainerio E,Tonello C,Dioni L,Briscini L,Redaelli G,Molinari E,Cavagnini F,Carruba MO. D2 dopamine receptor (DRD2) gene Taq1A polymorphism and the eating-related psychological traits in eating disorders (anorexia nervosa and bulimia) and obesity. Eat Weight Disord 2007; 12: 916.